Results 81 to 90 of about 6,631 (200)

Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: a multiple regression analysis with proxies of healthcare need [PDF]

, 2005
Background There is a small, but growing body of literature highlighting inequities in GP practice prescribing rates for many drug therapies. The aim of this paper is to further explore the equity of prescribing for five major CHD drug groups and to ...
A Gibson, A Majeed, A Majeed, A Majeed, A Williams, AM Tod, Antony S St Leger, B Hope, BH Foundation, C Baxter, C Packham, C Packham, D Health, D Health, D Health, D Health, DC Lloyd, DC Lloyd, EUROASPIREII Group., FA Majeed, FA Majeed, FDA Reid, G Davey-Smith, G Davey-Smith, GC Fonarow, H Cooper, H Tunstall-Pedoe, J Bedson, J Hippisley-Cox, J Tudor Hart, JHS Unit, JI Mann, JY Nazroo, K Gardner, M Frischer, M Goddard, M Pringle, M Whitehead, M Whitehead, MC MacLeod, MG Hunink, MG Patel, N Bradshaw, N Chaturvedi, N Danchin, N Rice, NC Campbell, NHS Centre for Reviews and Dissemination, ON Statistics, P Jousilahti, P Primatesta, P Suadicani, P Townsend, Paul R Ward, Peter R Noyce, PG Steg, PH Whincup, PR Ward, PR Ward, PR Ward, PS Unit, PS Unit, R Bhopal, R Bhopal, RM Haynes, S Hopper, S Kerrison, S Langham, S Peckham, SM Bogle, SR Chapman, SS Gottlieb, T Crayford, T Morton-Jones, T Walley, TJ Wang, V Salomaa, WH Organisation.   +77 more
core   +4 more sources

Advancing antihypertensive drug development

British Journal of Pharmacology, Volume 182, Issue 15, Page 3389-3410, August 2025.
Hypertension affects more than a billion individuals worldwide and remains a major cause of cardiovascular morbidity and mortality. Despite advances in therapies, optimal blood pressure control remains elusive for many patients because of treatment resistance, adverse effects, and adherence challenges.
Fay Pu, Yanrong Liu, Fozia Zahir Ahmed, Xin Wang, Darren Green, Hongyuan Zhang   +5 more
wiley   +1 more source

Trends and Predictors of Antihypertensive Medication Adherence in Commercially Insured Adults under 65 (2018–2023)

The Journal of Clinical Hypertension, Volume 27, Issue 8, August 2025.
ABSTRACT Understanding class‐specific antihypertensive adherence is crucial for optimizing hypertension management. This retrospective cohort study analyzed adherence to antihypertensive medication among commercially insured adults (18–64 years) from 2018 to 2023 using Merative MarketScan data.
N. M. Mahmudul Alam Bhuiya, Joshua Caballero, Henry N. Young, Lorenzo Villa Zapata   +3 more
wiley   +1 more source

Circulating microRNA Biomarkers of Thiazide Response in Hypertension

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Thiazide diuretics are the second most frequently prescribed class of antihypertensives, but up to 50% of patients with hypertension have minimal antihypertensive response to thiazides.
Lakshmi Manasa S. Chekka, Marwa Tantawy, Taimour Langaee, Danxin Wang, Rolf Renne, Arlene B. Chapman, John G. Gums, Eric Boerwinkle, Rhonda M. Cooper‐DeHoff, Julie A. Johnson   +9 more
doaj   +1 more source

Clinical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension

Vascular Health and Risk Management, 2012
Jerrica E Shuster,1,2 Barry E Bleske,1,2 Michael P Dorsch1,21University of Michigan Hospitals and Health Centers, Ann Arbor, MI, USA; 2College of Pharmacy, University of Michigan, Ann Arbor, MI, USAAbstract: Azilsartan–chlorthalidone fixed ...
Shuster JE, Bleske BE, Dorsch MP
doaj  

Comparative analysis of antihypertensive effects of chlorthalidone and indapamide-retard in combination with azilsartan medoxomil in patients with arterial hypertension

Российский кардиологический журнал, 2019
Achievement of target blood pressure (BP) is one of the key strategies of primary prevention of cardiovascular complications in patients with arterial hypertension (AH). Aim.
Zh. D. Kobalava, V. V. Kulakov, L. A. Goreva, S. V. Villevalde   +3 more
doaj   +1 more source

Drug-gene interactions of antihypertensive medications and risk of incident cardiovascular disease: a pharmacogenomics study from the CHARGE consortium [PDF]

, 2015
Background Hypertension is a major risk factor for a spectrum of cardiovascular diseases (CVD), including myocardial infarction, sudden death, and stroke.
Arnett, Donna, Avery, Christy L., Bis, Joshua C., Boerwinkle, Eric, Brody, Jennifer A., Buckley, Brendan M., Chen, Yii-Der Ida, Cummings, Steven R., Cupples, L. Adrienne, Davis, Barry R., de Craen, Anton J. M., Demissie, Serkalem, Eckfeldt, John H., Evans, Daniel S., Ford, Ian, Franco, Oscar H., Gudnason, Vilmundur, Harris, Tamara B., Heckbert, Susan R., Hofman, Albert, Ikram, M. Arfan, Irvin, Ryan, Jukema, J. Wouter, Krijthe, Bouwe P., Lange, Leslie A., Launer, Lenore J., Li, Xiaohui, Liu, Yongmei, Lumley, Thomas, Musani, Solomon K., Post, Wendy, Psaty, Bruce M., Quibrera, P. Miguel, Rotter, Jerome I., Sattar, Naveed, Sitlani, Colleen, Slagboom, P. Eline, Smith, Albert Vernon, Smith, Nicholas L., Sotoodehnia, Nona, Stott, David J., Stricker, Bruno H., Stürmer, Til, Sun, Fangui, Taylor, Herman A., Taylor, Kent D., Tranah, Gregory J., Trompet, Stella, Uitterlinden, Andre G., Vasan, Ramachandran S., Westendorp, Rudi, Whitsel, Eric A., Wiggins, Kerri L., Wilson, James G.   +53 more
core   +4 more sources

Modern approaches to the treatment and long-term management of arterial hypertension in clinical practice. Pharmacological and clinical characteristics of angiotensin II receptor blockers: focus on azilsartan medoxomil. Part II

КардиоСоматика, 2015
The article discusses the problem of the use for the treatment of hypertension combination therapy. Advantages of application as a component of chlorthalidone therapy are discussed.
M. G Bubnova
doaj  

Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER‐Prevention Randomized Clinical Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
Background Prehypertension is associated with higher cardiovascular risk, target organ damage, and incidence of hypertension. The Prevention of Hypertension in Patients with PreHypertension (PREVER‐Prevention) trial aimed to evaluate the efficacy and ...
Sandra Costa Fuchs, Carlos E. Poli‐de‐Figueiredo, José A. Figueiredo Neto, Luiz César N. Scala, Paul K. Whelton, Francisca Mosele, Renato Bandeira de Mello, José F. Vilela‐Martin, Leila B. Moreira, Hilton Chaves, Marco Mota Gomes, Marcos R. de Sousa, Ricardo Pereira e Silva, Iran Castro, Evandro José Cesarino, Paulo Cesar Jardim, João Guilherme Alves, André Avelino Steffens, Andréa Araujo Brandão, Fernanda M. Consolim‐Colombo, Paulo Ricardo de Alencastro, Abrahão Afiune Neto, Antônio C. Nóbrega, Roberto Silva Franco, Dario C. Sobral Filho, Alexandro Bordignon, Fernando Nobre, Rosane Schlatter, Miguel Gus, Felipe C. Fuchs, Otávio Berwanger, Flávio D. Fuchs   +31 more
doaj   +1 more source

The effect of chlorthalidone on cardiovascular and renal disease: A systematic review [PDF]

Journal of Research in Clinical Medicine
Introduction: Hypertension is a significant risk factor for cardiovascular disease (CVD), including coronary artery disease, cerebrovascular disease, peripheral artery disease, and arteriosclerosis.
Suryono Suryono, Hana Nadya, Wahyu Ikhsan, Achmad Ilham Tohari, Hazbina Fauqi Ramadhan   +4 more
doaj   +1 more source